Meeting Information - The second extraordinary general meeting of shareholders for 2025 is scheduled for September 8, 2025, at 14:00 [1] - The meeting will be held at the company's conference room located at No. 18, Huagong Road, Huabu Town, Kaihua County, Quzhou City, Zhejiang Province [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting times include trading hours: 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders holding multiple accounts can exercise voting rights across all accounts, but repeated votes will be counted based on the first submission [3][4] Agenda Items - The meeting will review a proposal regarding the completion and termination of certain fundraising investment projects and the permanent allocation of surplus funds to working capital [2] - This proposal has already been approved by the company's board and supervisory committee [2] Attendance Requirements - Shareholders registered by the close of business on September 1, 2025, are eligible to attend the meeting [5] - Attendees must provide identification and, if applicable, authorization documents for representatives [5] Additional Information - The meeting will last half a day, and attendees are responsible for their own travel and accommodation expenses [5] - Contact information for inquiries includes an email address and phone number for the company [5]

Core Viewpoint - The company, Zhejiang Huakang Pharmaceutical Co., Ltd., has decided to terminate certain fundraising investment projects and permanently supplement the remaining funds into working capital, along with the cancellation of the fundraising special account [2][12]. Fundraising Basic Situation - The company raised a total of RMB 150,449.82 million from its initial public offering, with a net amount of RMB 137,477.15 million after deducting issuance costs of RMB 12,972.67 million [2][3]. Overview of Fundraising Investment Projects - The company has made several changes to its fundraising investment projects, including the termination of the "Viscose Fiber Press Liquid Comprehensive Utilization Industrialization Project" and reallocating funds to the "Annual Production of 30,000 Tons of High-Purity Crystalline Erythritol Construction Project" [3][4]. - The remaining unallocated funds of RMB 2,528.75 million were to be managed in a special fundraising account [3]. Project Termination and Adjustments - In 2024, the company decided to terminate the "Functional Sugar Alcohol Technology R&D Center Construction Project" and reallocate the remaining funds of RMB 12,963.95 million to working capital [5][8]. - The company adjusted the internal investment structure of the R&D center project, increasing construction investment by RMB 2,000.00 million and reducing equipment investment by the same amount [5][8]. Remaining Fund Usage Plan - The remaining funds after project termination will be permanently supplemented into working capital to enhance operational efficiency and maximize shareholder value [11][12]. Approval Procedures - The company has followed necessary internal approval procedures for the termination of fundraising investment projects and the reallocation of funds, ensuring compliance with relevant regulations [12][14].

2025半年度基础化工行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额（万 | | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | （股） | （元） | 元） | | （%） | （%） | | 600096 | 云天化 | 0.00 | 2 | 36459.81 | 13.20 | | 0.90 | | 600273 | 嘉化能 源 | 0.00 | 2 | 26507.07 | 45.66 | | 2.47 | | 603113 | 金能科 技 | 0.00 | 2.35 | 19926.88 | 753.81 | | 3.84 | | 002749 | 国光股 | 0.00 | 4 | 18654.34 | 80.92 | | 2.71 | 8月21日华康股份发布2025半年度分配预案，拟10派2元（含税），预计派现金额合计为6061.00万元。 派现额占净利润比例为45.33%，这是公司上市以来，累计第6次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，华康股份发布公告称，2025年半年度公司实现营业收入1，865，861， 711.37元，同比增长37.32%；归属于上市公司股东的净利润为133，705，194.39元，同比下降3.38%。 ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，华康股份发布公告称，公司第六届监事会第二十一次会议审议通过了《关 于公司2025年半年度报告及其摘要的议案》等多项议案。 ...

证券日报网讯 8月21日晚间，华康股份发布关于公司2025年中期利润分配预案的公告称，公司拟向全体 股东每10股派发现金红利2元（含税），截至2025年8月20日公司总股本为30，304.9751万股，以此计算 拟分配的股本，拟派发现金红利6，060.99502万元（含税），本年度公司现金分红占公司2025年半年度 归属于上市公司股东净利润的比率为45.33%。 （编辑 任世碧） ...

Core Viewpoint - Huakang Co., Ltd. reported a revenue of 1.866 billion yuan for the first half of 2025, marking a year-on-year increase of 37.32%, while the net profit attributable to shareholders decreased by 3.38% to 134 million yuan [1] Financial Performance - The company achieved an operating income of 1.866 billion yuan, reflecting a growth of 37.32% compared to the previous year [1] - The net profit attributable to shareholders was 134 million yuan, which represents a decline of 3.38% year-on-year [1] - Basic earnings per share stood at 0.45 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1] Factors Affecting Performance - The decline in net profit is primarily attributed to the increase in liquid product business in Zhoushan, changes in the sales product structure leading to a decrease in gross margin, and increased financial expenses due to the capitalization of convertible bond interest [1]

Group 1 - The company Huakang Co., Ltd. (SH 605077) announced the convening of its 32nd meeting of the 6th Board of Directors on August 21, 2025, which was held in a hybrid format of in-person and communication [2] - The meeting reviewed the proposal regarding the company's half-year report for 2025 and its summary [2] - For the year 2024, the company's revenue composition indicates that the agricultural and sideline food processing industry accounted for 99.51% of total revenue, while other businesses contributed 0.49% [2]

Core Viewpoint - Huakang Co., Ltd. reported a significant increase in revenue for the first half of 2025, while net profit experienced a slight decline compared to the previous year [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 1.866 billion yuan, representing a year-on-year increase of 37.32% [2] - The net profit attributable to shareholders of the listed company was around 134 million yuan, showing a year-on-year decrease of 3.38% [2] - Basic earnings per share were 0.45 yuan, which is a decrease of 2.17% year-on-year [2]

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares, based on the total share capital registered on the equity distribution date [1][2]. Summary by Sections Profit Distribution and Capital Increase Plan - As of June 30, 2025, the company has a distributable profit of 1,174.4735 million yuan [1]. - The proposed cash dividend distribution is based on the total share capital as of the equity distribution registration date, which is 30,304.9751 million shares as of August 20, 2025 [1]. - The cash dividend represents 45.33% of the company's net profit attributable to shareholders, with no capital increase from reserves planned [1]. Decision-Making Process - The company held the 32nd meeting of the sixth board of directors and the 21st meeting of the sixth supervisory board on August 21, 2025, where the profit distribution proposal was approved [2]. - The supervisory board believes the profit distribution plan considers the company's operational and financial status and aligns with relevant regulations, supporting sustainable development without harming the interests of the company and investors [2]. Additional Notes - If there are changes in total share capital due to convertible bonds, share buybacks, or other factors before the equity distribution registration date, the per-share distribution ratio will remain unchanged, and the total distribution amount will be adjusted accordingly [2]. - The profit distribution proposal is subject to approval at the company's second extraordinary general meeting of shareholders in 2025 [2].